AMLX · Amylyx Pharmaceuticals, Inc.
$31.84
-0.76% last session
End-of-day data · close of 2026-09-11
Market cap
$4B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-27.8
Dividend yield
—
Beta
-0.12
Avg volume
2M
Employees
0K
Daily Change %
-0.76%
5 Days Change
-4.99%
10 Days Change
-4.00%
30 Days Change
37.11%
60 Days Change
82.33%
Month to Day Change
-4.17%
Year to Day Change
168.21%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — AMLX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-27
Latest call per bank · past 12 months
Citigroup
Buy$26.00
-19.0% vs priceBank of America
Buy$19.00
-40.8% vs priceGoldman Sachs
Buy$20.00
-37.7% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-27 | Guggenheim | Maintains | Buy | $55.00 → $57.00 |
| 2026-08-19 | Mizuho | Maintains | Outperform | $30.00 → $42.00 |
| 2026-08-19 | Guggenheim | Maintains | Buy | $40.00 → $55.00 |
| 2026-08-19 | Baird | Maintains | Outperform | $28.00 → $52.00 |
| 2026-08-18 | HC Wainwright & Co. | Maintains | Buy | $34.00 → $55.00 |
| 2026-08-17 | Mizuho | Maintains | Outperform | $24.00 → $30.00 |
| 2026-08-03 | Citigroup | Maintains | Buy | $20.00 → $26.00 |
| 2026-07-20 | Mizuho | Maintains | Outperform | $21.00 → $24.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 25.5% above the 50-day MA ($25.38).
- Price vs 200-day MA: Trading 84.7% above the 200-day MA ($17.24).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.97) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($11.38) and high ($39.66).
AMLX Price Chart
Loading chart for AMLX…
Fundamentals
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$58B 16.8% YTD
TEVA
Teva Pharmaceutical Industries
$42B 18.1% YTD
HLN
Haleon plc
$41B -6.9% YTD
ZTS
Zoetis Inc.
$30B -40.8% YTD
UTHR
United Therapeutics Corporation
$22B 4.0% YTD
VTRS
Viatris Inc.
$19B 35.6% YTD
NBIX
Neurocrine Biosciences, Inc.
$16B 9.4% YTD
ELAN
Elanco Animal Health Incorporat
$11B 4.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.